FIELD: medicine.
SUBSTANCE: invention relates to medicine and can be used in therapy. The method for evaluating the effectiveness of the treatment of pneumonia is to study a general blood test before and after treatment. At the same time, the amount of C-reactive protein, the activity of catalase, superoxide dismutase, elastase- and trypsin-like proteinases in the blood serum are additionally determined and the discriminant functions of Y1 and Y2 are calculated. When Y2 is greater than Y1 and with a decrease of 20% or more in ESR, the activity of elastase-like proteinases by 35% or more, the number of leukocytes by 40% or more, the activity of trypsin-like proteinases by 50% or more, catalase activity by 50% or more at normal (23.1±3.1) mcmol/l, SOD activity by 50% or more, as well as the level of TBA-active compounds by 50% or more, the amount of C-reactive protein by 50% or more after treatment compared to the level before treatment, the treatment of pneumonia with interstitial type of infiltration in the lung tissue is evaluated as effective.
EFFECT: invention provides increased accuracy of evaluating effectiveness of the treatment of pneumonia.
1 cl, 4 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DIFFERENTIAL DIAGNOSIS OF PULMONARY TISSUE INFILTRATION TYPE IN PNEUMONIA | 2020 |
|
RU2738450C1 |
METHOD FOR EVALUATING EFFECTIVENESS OF TREATMENT OF PNEUMONIA | 2020 |
|
RU2753744C1 |
DIAGNOSTIC METHOD OF COMATOSE STATE IN CASE OF PNEUMONIA | 2020 |
|
RU2738442C1 |
METHOD FOR PREDICTING COURSE OF PNEUMONIA WITH ALVEOLAR TYPE OF LUNG TISSUE INFILTRATION | 2020 |
|
RU2753745C1 |
METHOD FOR DETECTING MICROCIRCULATORY DISORDERS AS A BIOMARKER OF INTERSTITIAL CHANGES IN THE LUNGS OF PATIENTS UNDERGONE A NEW CORONAVIRUS INFECTION | 2022 |
|
RU2790513C1 |
METHOD FOR PREDICTING OUTCOME OF INFECTIOUS PROCESS AFTER A NEW CORONAVIRUS INFECTION FOR 12 MONTHS | 2023 |
|
RU2807384C1 |
METHOD FOR EARLY DIFFERENTIAL DIAGNOSIS OF VIRAL AND BACTERIAL COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN | 2022 |
|
RU2790239C1 |
METHOD FOR ASSESSING ENDOMETRIAL CANCER PROGRESSION IN PATIENTS WITH HYPERPLASTIC PROCESSES IN ENDOMETRIUM | 2014 |
|
RU2554505C1 |
METHOD FOR EVALUATING THE DEGREE OF RISK OF ADVERSE EVALUATION OF DISEASE IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2662085C1 |
MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
Authors
Dates
2021-08-23—Published
2020-06-16—Filed